A deep learning radiomic biomarker has been developed and validated to predict responses to immune checkpoint inhibitors in ...
New data suggests researchers may have found one of their most promising candidates yet for the next generation in ...
Find out more about the emerging field of glycobiology, which could potentially lead to a new type of cancer immunotherapy.
A recent study highlights an increased risk of thromboembolic events in metastatic lung cancer patients treated with immune ...
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies ...
New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.
Immunotherapies have become a cornerstone in cancer treatment, with current therapies like checkpoint inhibitors enhancing ...
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...
CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results